510(k) Report

510(k) · Cleared

Cleared

MamaLift Plus

K223515510(k) TraditionalCleared Apr 22, 2024517-day reviewClass II21 CFR 882.5801

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Curio Digital Therapeutics, Inc. · SAP Computerized Behavioral Therapy Device For Depressive Disorders.

Cleared on Apr 22, 2024 as substantially equivalent to K191716 (Pear Therapeutics, Inc., 2020) after a 517-day review. Its family tree reaches back 2 generations to 2017.

Decided
Apr 22, 2024
Review
517 days
Class
Class II
Product code
SAP
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN160018 (2017). No later device cites it as a predicate yet.

DEN160018 · reSet · Pear Therapeutics, Inc. · 2017K191716 · Somryst · Pear Therapeutics, Inc. · 2020201620182020202220242026
  1. Root · 2 generations backDEN160018 reSetPear Therapeutics, Inc. · 2017
  2. 1 generation backK191716 SomrystPear Therapeutics, Inc. · 2020
  3. This deviceK223515 MamaLift PlusCurio Digital Therapeutics, Inc. · 2024
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN160018reSetPear Therapeutics, Inc.2017—
−1K191716SomrystPear Therapeutics, Inc.2020—
0 (this device)K223515MamaLift PlusCurio Digital Therapeutics, Inc.2024—
FIG. 1 — Lineage of K223515, 2017–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in SAP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new SAP device

  1. #1 K254038 Motivista (CT-155)score 12.1 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K191716Somryst
Summary page 4
…hiatric Disorders Product Code: SAP Product Code Name: Computerized behavioral therapy device for depressive disorders. Regulatory Class: II Predicate Device: Somryst™ (K191716) by Pear Therapeutics Inc., a cognitive behavioral therapy for insomnia (CBT‐I) via a mobile application). Trade/Device Name: Som…
Pear Therapeutics, Inc.2020—

Also cleared against K191716: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 7 years and passes through 2 companies; a new generation was cleared every 4.1 years on median.
  • None of the 2 ancestors has a recall.
  • 2 other devices also cite its predicate K191716.

How does its category compare?

All SAP devices

SAP Computerized Behavioral Therapy Device For Depressive Disorders.: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · SAP

2in 2024

2024: 22026 (partial year): 1
2007high 2 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · SAP

Too few SAP 510(k)s in any year since 2007 to give a median.

Recalls per year · SAP

No recall names SAP since 2007.

Adverse event reports per year · SAP

No MAUDE report names SAP since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20242—00
20250—00
20261—0—

What is it indicated for?

MamaLift Plus is a prescription-only digital therapeutic intended to provide neurobehavioral interventions to patients 22 years of age and older, as an adjunct to clinician-managed outpatient care. MamaLift Plus treats mild to moderate postpartum depression by improving a patient's symptoms of depression.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K223515: MamaLift Plus.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K223515

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026